US Food and Drug Administration approval comes a week after European heart experts endorsed the longer-term exhaust of BrilintaAstraZeneca received a much-needed boost when its blood-thinning drug,Brilinta, a potential blockbuster, and was approved by the US health regulator for wider exhaust.The Food and Drug Administration approved Brilinta tablets for longer-term exhaust in patients with a history of heart attack. The new 60mg dose can be taken twice a day along with aspirin beyond a year after a heart attack. Until now,the blood thinner could only be prescribed for one year after a heart attack, as a 90mg dose.
Continue reading...
Source: theguardian.com